Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Neisseria Adhesin A Variation and Revised Nomenclature Scheme

Neisseria Adhesin A Variation and Revised Nomenclature Scheme Neisseria Adhesin A Variation and Revised Nomenclature Scheme Stefania Bambini a , Matteo De Chiara a , Alessandro Muzzi a , Marirosa Mora a , Jay Lucidarme b , Carina Brehony c , Ray Borrow b , Vega Masignani a , Maurizio Comanducci a * , Martin C. J. Maiden c , Rino Rappuoli a , Mariagrazia Pizza a and Keith A. Jolley c a Novartis Vaccines and Diagnostics, Siena, Italy b Public Health England, Manchester, United Kingdom c Department of Zoology, University of Oxford, Oxford, United Kingdom D. L. Burns , Editor ABSTRACT Neisseria adhesin A (NadA), involved in the adhesion and invasion of Neisseria meningitidis into host tissues, is one of the major components of Bexsero, a novel multicomponent vaccine licensed for protection against meningococcal serogroup B in Europe, Australia, and Canada. NadA has been identified in approximately 30% of clinical isolates and in a much lower proportion of carrier isolates. Three protein variants were originally identified in invasive meningococci and named NadA-1, NadA-2, and NadA-3, whereas most carrier isolates either lacked the gene or harbored a different variant, NadA-4. Further analysis of isolates belonging to the sequence type 213 (ST-213) clonal complex identified NadA-5, which was structurally similar to NadA-4, but more distantly related to NadA-1, -2, and -3. At the time of this writing, more than 89 distinct nadA allele sequences and 43 distinct peptides have been described. Here, we present a revised nomenclature system, taking into account the complete data set, which is compatible with previous classification schemes and is expandable. The main features of this new scheme include (i) the grouping of the previously named NadA-2 and NadA-3 variants into a single NadA-2/3 variant, (ii) the grouping of the previously assigned NadA-4 and NadA-5 variants into a single NadA-4/5 variant, (iii) the introduction of an additional variant (NadA-6), and (iv) the classification of the variants into two main groups, named groups I and II. To facilitate querying of the sequences and submission of new allele sequences, the nucleotide and amino acid sequences are available at http://pubmlst.org/neisseria/NadA/ . http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical and Vaccine Immunology American Society For Microbiology

Neisseria Adhesin A Variation and Revised Nomenclature Scheme

Clinical and Vaccine Immunology , Volume 21 (7): 966 – Jul 1, 2014

Abstract

Neisseria Adhesin A Variation and Revised Nomenclature Scheme Stefania Bambini a , Matteo De Chiara a , Alessandro Muzzi a , Marirosa Mora a , Jay Lucidarme b , Carina Brehony c , Ray Borrow b , Vega Masignani a , Maurizio Comanducci a * , Martin C. J. Maiden c , Rino Rappuoli a , Mariagrazia Pizza a and Keith A. Jolley c a Novartis Vaccines and Diagnostics, Siena, Italy b Public Health England, Manchester, United Kingdom c Department of Zoology, University of Oxford, Oxford, United Kingdom D. L. Burns , Editor ABSTRACT Neisseria adhesin A (NadA), involved in the adhesion and invasion of Neisseria meningitidis into host tissues, is one of the major components of Bexsero, a novel multicomponent vaccine licensed for protection against meningococcal serogroup B in Europe, Australia, and Canada. NadA has been identified in approximately 30% of clinical isolates and in a much lower proportion of carrier isolates. Three protein variants were originally identified in invasive meningococci and named NadA-1, NadA-2, and NadA-3, whereas most carrier isolates either lacked the gene or harbored a different variant, NadA-4. Further analysis of isolates belonging to the sequence type 213 (ST-213) clonal complex identified NadA-5, which was structurally similar to NadA-4, but more distantly related to NadA-1, -2, and -3. At the time of this writing, more than 89 distinct nadA allele sequences and 43 distinct peptides have been described. Here, we present a revised nomenclature system, taking into account the complete data set, which is compatible with previous classification schemes and is expandable. The main features of this new scheme include (i) the grouping of the previously named NadA-2 and NadA-3 variants into a single NadA-2/3 variant, (ii) the grouping of the previously assigned NadA-4 and NadA-5 variants into a single NadA-4/5 variant, (iii) the introduction of an additional variant (NadA-6), and (iv) the classification of the variants into two main groups, named groups I and II. To facilitate querying of the sequences and submission of new allele sequences, the nucleotide and amino acid sequences are available at http://pubmlst.org/neisseria/NadA/ .

Loading next page...
 
/lp/american-society-for-microbiology/neisseria-adhesin-a-variation-and-revised-nomenclature-scheme-y7raz0cMF6

References

References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.

Publisher
American Society For Microbiology
Copyright
Copyright © 2014 by the American society for Microbiology.
ISSN
1556-6811
eISSN
1556-679X
DOI
10.1128/CVI.00825-13
pmid
24807056
Publisher site
See Article on Publisher Site

Abstract

Neisseria Adhesin A Variation and Revised Nomenclature Scheme Stefania Bambini a , Matteo De Chiara a , Alessandro Muzzi a , Marirosa Mora a , Jay Lucidarme b , Carina Brehony c , Ray Borrow b , Vega Masignani a , Maurizio Comanducci a * , Martin C. J. Maiden c , Rino Rappuoli a , Mariagrazia Pizza a and Keith A. Jolley c a Novartis Vaccines and Diagnostics, Siena, Italy b Public Health England, Manchester, United Kingdom c Department of Zoology, University of Oxford, Oxford, United Kingdom D. L. Burns , Editor ABSTRACT Neisseria adhesin A (NadA), involved in the adhesion and invasion of Neisseria meningitidis into host tissues, is one of the major components of Bexsero, a novel multicomponent vaccine licensed for protection against meningococcal serogroup B in Europe, Australia, and Canada. NadA has been identified in approximately 30% of clinical isolates and in a much lower proportion of carrier isolates. Three protein variants were originally identified in invasive meningococci and named NadA-1, NadA-2, and NadA-3, whereas most carrier isolates either lacked the gene or harbored a different variant, NadA-4. Further analysis of isolates belonging to the sequence type 213 (ST-213) clonal complex identified NadA-5, which was structurally similar to NadA-4, but more distantly related to NadA-1, -2, and -3. At the time of this writing, more than 89 distinct nadA allele sequences and 43 distinct peptides have been described. Here, we present a revised nomenclature system, taking into account the complete data set, which is compatible with previous classification schemes and is expandable. The main features of this new scheme include (i) the grouping of the previously named NadA-2 and NadA-3 variants into a single NadA-2/3 variant, (ii) the grouping of the previously assigned NadA-4 and NadA-5 variants into a single NadA-4/5 variant, (iii) the introduction of an additional variant (NadA-6), and (iv) the classification of the variants into two main groups, named groups I and II. To facilitate querying of the sequences and submission of new allele sequences, the nucleotide and amino acid sequences are available at http://pubmlst.org/neisseria/NadA/ .

Journal

Clinical and Vaccine ImmunologyAmerican Society For Microbiology

Published: Jul 1, 2014

References